Biomarkers in heart failure with preserved ejection fraction (pilot)
Research type
Research Study
Full title
Circulating levels of Matricellular proteins as markers to distinguish between different forms of heart failure: A pilot study
IRAS ID
135021
Contact name
John P Greenwood
Contact email
Research summary
Heart failure (HF) is rapidly becoming the predominant cardiovascular disorder in the Western world, having an unparalled impact on both public health and health care delivery. It is estimated that in the UK alone over 750,000 people are living with HF and there are 27,000 new cases each year. Over half of patients that present in clinic with heart failure (HF) have a normal or preserved left ventricular ejection fraction (HFpEF). Patients with HFpEF have a similar prognosis to patients with HF due to reduced ejection fraction (HFrEF) but as yet no specific treatment has been shown to reduce their morbidity and mortality. The diagnosis of HFpEF remains challenging, with current algorithms based on clinical evaluation, indices derived from tissue Doppler echocardiography, (which are not without their short comings) and invasive assessment of hemodynamic parameters. There remains an unmet clinical need for sensitive minimally invasive biomarkers that can be exploited to assist in early detection of HFpEF, monitor response to therapy and allow intervention before irreversible cardiac damage is established. The primary aim of this pilot study is to determine if specific biomarker profiles, based on plasma matricellular protein levels, can either independently or in combination with NT-pro–BNP, better differentiate stable patients with HFpEF from those with HFrEF.
REC name
Yorkshire & The Humber - Leeds East Research Ethics Committee
REC reference
13/YH/0267
Date of REC Opinion
10 Sep 2013
REC opinion
Further Information Favourable Opinion